*1.What is your degree?(Required.)

MD/DO

PA

NP

RN

Other (please specify)

*2.What is your specialty?(Required.)

Medical oncology

Surgical oncology

Radiation oncology

Pulmonology

Pathology

Other (please specify)

*3.How confident are you in the management of patients with ES-SCLC in your practice?(Required.)

Very confident

Confident

Neutral

Little confidence

No confidence

*4.What is the estimated likelihood for a duration of response (DOR) ≥ 12 months for a patient with ES-SCLC who receives third-line single-agent immunotherapy?(Required.)

0% to 10%

20% to 30%

40% to 50%

60% to 70%

*5.Which treatment option is most appropriate for a patient with ES-SCLC who experiences disease relapse 8 months after completing first-line chemotherapy?(Required.)

Chemo rechallenge

Clinical trial

Lurbinectedin

Topotecan

*6.Which of the following FDA-approved, guideline-recommended treatment regimens would you prescribe as second-line therapy for a 67-year-old female patient with ES-SCLC and disease recurrence after 2 cycles of chemo/ICI therapy?(Required.)

Chemo rechallenge

Lurbinectedin

Nivolumab

Pembrolizumab

*7.One of your patients with SCLC successfully stopped smoking with combination nicotine replacement therapy (NRT; nicotine patch and gum). At a follow-up visit 2 months later, the patient reports that they have resumed smoking. What NCCN-preferred smoking cessation regimen would you recommend?(Required.)

Bupropion

Bupropion + NRT

Varenicline

Varenicline + NRT